AstraZeneca PLC has grown revenue 9.8% a year over three years and 17% a year over five, with earnings per share compounding at 46%. Revenue growth, 3-year annual rate: +9.8% (Drug Manufacturers - General median +6.3%). Revenue growth, 5-year rate: +17%, growth has slowed since the five-year average. Earnings per share, 3-year rate: +46%, earnings outgrew revenue: margins or the share count worked for shareholders. Years of annual history on file: 11, FY2015 to FY2025, as filed.

AZNAstraZeneca PLC

HealthcareUSD

$166.29

$145.5452 weeks$208.62

Is it growing?

Is AZN growing?

AstraZeneca PLC has grown revenue 9.8% a year over three years and 17% a year over five, with earnings per share compounding at 46%.

+9.8%

Revenue growth, 3-year annual rate · Drug Manufacturers - General median +6.3% · steady growth, ahead of inflation · compounded from fiscal-year columns as filed

Revenue growth, 5-year rate: +17%
Revenue growth, 5-year rate · +9.8% over three · growth has slowed since the five-year average
Earnings per share, 3-year rate: +46%
Earnings per share, 3-year rate · revenue +9.8% · earnings outgrew revenue: margins or the share count worked for shareholders
Years of annual history on file: 11
Years of annual history on file · FY2015 to FY2025, as filed